Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Key developments in molecular profiling for Hodgkin lymphoma

Julia Driessen • 4 Jun 2021
EHA 2021
Hodgkin Lymphoma Lymphoma

Julia Driessen, MBBS, University of Amsterdam, Amsterdam, The Netherlands, discusses the key developments in the molecular profiling of Hodgkin lymphoma which we can expect to see over the next couple of years, in particular highlighting advances in radiomics and the potential role of circulating tumor DNA (ctDNA). This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Julia Driessen

2:15
Current and emerging treatment options for Hodgkin lymphoma
Julia Driessen • 14 Dec 2021
3:47
Brentuximab vedotin plus chemotherapy prior to ASCT in R/R Hodgkin lymphoma
Julia Driessen • 14 Dec 2021
2:27
Predictive value of 18F-FDG-PET radiomics in R/R Hodgkin lymphoma
Julia Driessen • 4 Jun 2021
2:15
HOVON/LLPC Transplant BRaVE: novel salvage chemotherapy for R/R Hodgkin lymphoma
Julia Driessen • 4 Jun 2021

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals